Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion

Annals of Internal Medicine

Volumn 131, Issue 7, 1999, Pages 502-506

  Brodine, Stephanie K ^a   Shaffer, Richard A ^b   Starkey, Monica J ^b   Tasker, Sybil A ^b   Gilcrest, Joyce L ^b   Louder, Mark K ^c   Barile, Anthony ^d   VanCott, Thomas C ^e   Vahey, Maryanne T ^f   McCutchan, Francine E ^e   Birx, Deborah L ^f   Richman, Douglas D ^g   Mascola, John R ^f  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c Building 304 ^*  (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SERODIAGNOSIS; SOLDIER; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 0033527423     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-7-199910050-00004     Document Type: Article

References (20)

1. Brodine SK, Mascola JR, McCutchan FE. Genotypic variation and molecular epidemiology of HIV. Infections in Medicine, 1997;14:739-48.
2. Hu DJ, Dondero TJ, Rayfield MA, George JR, Schochetman G, Jaffe HW, et al. The emerging diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA. 1996;275:210-6.
3. Rayfield MA, Sullivan P, Bandea CI, Britvan L, Otten RA, Pau CP, et al. HIV-1 group O virus identified for the first time in the United States. Emerg Inf Dis. 1996;2:209-12.
4. Schable C, Zekeng L, Pau CP, Hu D, Kaptue L, Gurtler L, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet. 1994;344:1333-4.
5. Debyser Z, Van Wijngaerden E, Van Laethem K, Beuselinck, K, Reynders M, De Clerq E, et al. Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. AIDS Res Hum Retroviruses. 1998;14:453-9.
6. Nolte FS, Boysza J, Thurmond C, Clark WS, Lennox JL. Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998;36:716-20.
7. Brodine SK, Mascola JR, Weiss PJ, Ito SI, Porter KR, Artenstein AW, et al. Detection of diverse HIV-1 genetic subtypes in the USA. Lancet. 1995;346: 1198-9.
8. Irwin KL, Pau CP, Lupo D, Pienazek D, Luo CC, Olivo N, et al. Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. J Infect Dis. 1997;176:1629-33.
9. Levin LI, Peterman TA, Renzullo PO, Lasley-Bibbs V, Shu XO, Brundage JF, et al. HIV-1 seroconversion and risk behaviors among young men in the US army. The Seroconversion Risk Factor Study Group. Am J Public Health. 1995;85:1500-6.
10. Gaywee J, Artenstein AW, VanCott TC, Trichavaroj R, Sukchamnong A, Amlee P, et al. Correlation of genetic and seroiogic approaches to HIV-1 subtyping in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 13:392-6.
11. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society -USA Panel. JAMA. 1998;279:1984-91.
12. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-83.
13. Gomez-Cano M, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Soriano V, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS. 1998;12:1015-20.
14. Mayers DL. Drug resistant HIV-1: the virus strikes back [Editorial]. JAMA. 1998;279:2000-2.
15. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-11.
16. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV-infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998;339:1261-8.
17. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses. 1998;14:157-62.
18. Hawkes S, Hart G. The sexual health of travelers. Infect Dis Clin North Am. 1998;12:413-30.
19. Auerbach JD. The role of behavioral research in HIV/AIDS prevention. Current Opinion in Infectious Diseases. 1998;3-7.
20. Pinkerton SD, Holtgrave DR, Wayne J, DiFranceisco WJ, Stevenson LY, Kelly JA. Cost-effectiveness of a community-level HIV risk reduction intervention. Am J Public Health. 1998;88:1239-42.